Kaleido Scope15h
Study reveals the disruption of interaction between proteins CD2:CD58 is a potential new treatment option for people with hidradenitis suppurativa
CD2 through its interaction with the cell surface protein, CD58, has critical functions for the activation of T cells and ...
Joplin Globe1d
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...
emjreviews.com1d
Low-Dose IL-2 Shows Promise for Allergic Rhinitis Relief
Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.
The Globe and Mail1d
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local production and secretion of the IL ... were enrolled in ...